TheScreener - Lumos Pharma Inc. (NLNK) NEWLINK GENETICS CORP. suffers a double requalification, which weighs heavily on its rating, now at Negative.

Report

TheScreener

EUR 13.82 For Business Accounts Only

NEWLINK GENETICS CORP. suffers a double requalification, which weighs heavily on its rating, now at Negative.

The independent financial analyst theScreener just downgraded the general evaluation of NEWLINK GENETICS CORP. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Negative. As of the analysis date January 24, 2020, the closing price was USD 1.82 and its target price was estimated at USD 1.25.

25/01/2020 6 EN

Underlying

Lumos Pharma Inc.

NewLink Genetics is a clinical-stage immuno-oncology company focused on discovering and developing immunotherapeutic products for the treatment of patients with cancer. The company's small-molecule product candidates in clinical development target the indoleamine-2, 3-dioxygenase (IDO) pathway. The company's product candidates include: indoximod and NLG802 (a prodrug of indoximod), which are IDO pathway inhibitors with mechanisms of action that center around breaking the immune system's tolerance to cancer; and NLG207, which is a nanoparticle-drug conjugate consisting of a cyclodextrin-based polymer backbone linked to camptothecin, a topoisomerase 1 inhibitor of the topoisomerase-1 inhibitor, camptothecin.

See profile

US6515111077 United States

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

GlobeNewsWire

Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board

Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the appointment of Joseph S. McCracken, DVM, MS to the company's Board of Directors, effective March 23, 2020. Dr. McCracken has extensive experience in the pharmaceutical and biotechnology industry, with prominent roles in business development, commercial development, and positions as board member for s...

March 30, 2020 March 30, 2020 1 EN

GlobeNewsWire

NewLink Genetics Stockholders Approve Merger with Lumos Pharma

NewLink Genetics Stockholders Approve Merger with Lumos Pharma - Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash on March 31, 2020 in excess of $80 million expected to be sufficient to fund company through Phase 2b trial in PGHD data read-out AUSTIN, Texas and AMES, Iowa, March 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (Lumos Pharma) and NewLink Genetics Corpora...

March 18, 2020 March 18, 2020 1 EN

GlobeNewsWire

NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Special Meeting of Stockholders set for March 17, 2020 for vote on proposed merger of NewLink Genetics and Lumos Pharma AMES, Iowa, Feb. 28, 2020 (GLOBE NEWSWIRE) -- (NASDAQ:NLNK) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on corporate activities. “We continue to focus our work toward the anticipated completion of our proposed merger with Lumos Pharma,” stated Carl Langren, Chief Financial Officer, and me...

February 28, 2020 February 28, 2020 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

NEWLINK GENETICS CORP. suffers a double requalification, which weighs heavily on its rating, now at Negative.

Empowering Investors

Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board

NewLink Genetics Stockholders Approve Merger with Lumos Pharma

NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe